12,955 Shares in Bristol Myers Squibb Company $BMY Purchased by Investment Research Partners LLC

Investment Research Partners LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY) during the third quarter, Holdings Channel.com reports. The institutional investor bought 12,955 shares of the biopharmaceutical company’s stock, valued at approximately $552,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Bristol Myers Squibb by 0.5% during the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after purchasing an additional 1,058,803 shares in the last quarter. State Street Corp raised its stake in Bristol Myers Squibb by 2.0% in the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock valued at $4,356,445,000 after purchasing an additional 1,855,238 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after purchasing an additional 10,195,775 shares in the last quarter. Norges Bank bought a new stake in Bristol Myers Squibb during the second quarter valued at approximately $1,554,154,000. Finally, Ameriprise Financial Inc. grew its stake in Bristol Myers Squibb by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after buying an additional 432,158 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 0.7%

Shares of BMY opened at $59.31 on Thursday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm has a market cap of $120.79 billion, a price-to-earnings ratio of 17.19, a PEG ratio of 0.17 and a beta of 0.26. The firm has a 50 day moving average price of $58.53 and a 200-day moving average price of $51.69. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BMY shares. Guggenheim reissued a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their target price for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Citigroup increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Leerink Partners raised their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Finally, UBS Group reaffirmed a “buy” rating and set a $70.00 price target on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $61.41.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.